Merdury Biopharmaceutical

Merdury Biopharmaceutical Current Assets

The Current Assets of Merdury Biopharmaceutical (6932.TWO) as of Oct 20, 2026 is 360,000.00 TWD. In the previous year, Current Assets was 181,000.00 TWD — a change of 98.90% (higher).

Current Assets

360,000.00TWD

YoY

98.90%

Last updated:

Current Assets of Merdury Biopharmaceutical is 2025 360,000.00 TWD. Current Assets of Merdury Biopharmaceutical was 2024 181,000.00 TWD. It decreases by 98.90% higher compared to the previous year.

The Merdury Biopharmaceutical Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
157,000.00 TWD
Jan 1, 2020
97,000.00 TWD
Jan 1, 2021
3.93 M TWD
Jan 1, 2022
145.73 M TWD
Jan 1, 2023
329.62 M TWD
Jan 1, 2024
181,000.00 TWD
Jan 1, 2025
360,000.00 TWD
The Merdury Biopharmaceutical Current Assets history
YEARCurrent AssetsYoY
360,000.00TWD+98.90%
181,000.00TWD-99.95%
329.62 MTWD+126.19%
145.73 MTWD+3,611.92%
3.93 MTWD+3,947.42%
97,000.00TWD-38.22%
157,000.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp develops and manufactures pharmaceutical products including Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, and multi-ingredient antihypertensive drugs. The company utilizes its StackDose platform to create controllable time-dissolving tablets for instant or sustained drug release. Products are primarily sold in Taiwan and the United States, targeting markets for drugs that do not meet special medical needs, difficult generics, and second-class new drugs. The company's revenue comes from the sale of these pharmaceutical products to customers in both regions. The firm's StackDose technology enables the development of specialized drug formulations that control the timing of drug effectiveness, differentiating its product range. This focus on innovative delivery systems supports sales in the pharmaceutical markets of Taiwan and the U.S., where demand exists for advanced generic and specialty medications. The company's product portfolio aligns with its strategic focus on non-special medical need drugs and second-class new drugs. Merdury Biopharmaceutical Corp targets healthcare providers and pharmacies in Taiwan and the United States as its primary customers. The company's self-developed StackDose platform allows for the creation of unique drug delivery systems that are sold under the company's own product lines. Sales of Sildenafil, Metformin, Tadalafil, and other key products form the core of the company's revenue streams. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

Current Assets of Merdury Biopharmaceutical is 360,000.00 TWD in 2025.

Current Assets of Merdury Biopharmaceutical changed from 181,000.00 TWD to 360,000.00 TWD, representing a 98.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Merdury Biopharmaceutical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical